| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5892076 | Bone | 2011 | 7 Pages |
Abstract
⺠With daily teriparatide, bone markers peak after 6-12 months and then decline. ⺠We randomized osteoporotic women to constant or escalating dose teriparatide. ⺠Escalating dose teriparatide prevented the decline in bone turnover markers. ⺠Nonetheless, bone density increases were equivalent to constant dose teriparatide.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Elaine W. Yu, Robert M. Neer, Hang Lee, Jason J. Wyland, Amanda V. de la Paz, Melissa C. Davis, Makoto Okazaki, Joel S. Finkelstein,